Shares of Fresenius Medical Care AG (NYSE:FMS - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 424,859 shares changed hands during mid-day trading, an increase of 68% from the previous session's volume of 252,772 shares.The stock last traded at $23.89 and had previously closed at $24.21.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on FMS. Bank of America raised Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research report on Monday, December 2nd. StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, Truist Financial boosted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th.
Get Our Latest Stock Analysis on Fresenius Medical Care
Fresenius Medical Care Trading Up 1.6 %
The firm's fifty day simple moving average is $23.51 and its 200-day simple moving average is $21.97. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock has a market cap of $14.05 billion, a P/E ratio of 19.81, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93.
Institutional Investors Weigh In On Fresenius Medical Care
Several large investors have recently added to or reduced their stakes in FMS. Callan Capital LLC acquired a new stake in shares of Fresenius Medical Care during the 4th quarter worth approximately $297,000. Sanctuary Advisors LLC acquired a new stake in shares of Fresenius Medical Care in the 4th quarter valued at about $983,000. ABC Arbitrage SA bought a new position in Fresenius Medical Care in the fourth quarter worth approximately $4,215,000. Verition Fund Management LLC bought a new stake in shares of Fresenius Medical Care during the third quarter valued at approximately $237,000. Finally, JPMorgan Chase & Co. raised its position in shares of Fresenius Medical Care by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company's stock worth $211,000 after purchasing an additional 1,528 shares during the period. Institutional investors and hedge funds own 8.37% of the company's stock.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
